The Lab (http://epigenomics.cemm.oeaw.ac.at/)
The Medical Epigenomics Lab at CeMM pursues an interdisciplinary and highly collaborative research program aimed at understanding the cancer epigenome and establishing its utility for precision medicine. The lab is internationally well connected and active in several fields:
- Bioinformatics. New computational methods enable the high-throughput analysis of disease mechanism and therapy responses. We develop algorithms for single-cell sequencing, multi-omics data analysis, and clinical time series.
- Epigenetics. Complex diseases are characterized by widespread deregulation of epigenetic cell states. We use epigenome technology to dissect the epigenetic basis of cancer and immune diseases and to identify new drug targets.
- Technology. Groundbreaking biomedical research is often driven by new technologies. Our lab is therefore heavily invested into technology development, including single-cell sequencing, CRISPR screens, and deep neural networks.
- Digital Medicine. New technologies in the area of genomics, imaging, and wearable sensors transform medicine into a ‘big data’ science. We employ machine learning / artificial intelligence to leverage such data for better patient care.
The Principal Investigator (https://scholar.google.com/citations?user=9qSsTcIAAAAJ)
Christoph Bock is a principal investigator at CeMM. His research focuses on bioinformatics, epigenetics, cancer biology, and high-throughput technology development. He is also a guest professor at the Medical University of Vienna, scientific coordinator of the Biomedical Sequencing Facility at CeMM, and adjunct group leader for bioinformatics at the Max Planck Institute for Informatics. He is a member of the Young Academy of the Austrian Academy of Sciences (since 2017) and recipient of several major research awards, including the Max Planck Society’s Otto Hahn Medal (2009), an ERC Starting Grant (2016-2021), and the Overton Prize of the International Society of Computational Biology (2017).
The Institute (http://www.cemm.at/)
CeMM is one of Europe’s leading biomedical research institutes. CeMM researchers routinely publish important discoveries in top journals. Over the last seven years, this included >10 papers in Nature/Cell/Science/NEJM and >30 papers in Nature/Cell sister journals – based on a team of 120-150 scientists. Research at CeMM is exceptionally collaborative and includes strong focus on medical impact, based on a profound molecular understanding of diseases such as cancer and immune disorders. CeMM is part of the Austrian Academy of Sciences and a founding member of EU-LIFE. It is located at the center of one of the largest medical campuses in Europe, within walking distance of Vienna’s historical city center. A study by “The Scientist” put CeMM among the top-5 best places to work in academia worldwide (https://www.the-scientist.com/features/best-places-to-work-academia-2012-40676). Vienna is frequently ranked the world’s best city to live. It is a United Nations city with a large English-speaking community. The official language at CeMM is English, and more than 40 different nationalities are represented at the institute. CeMM promotes equal opportunity and harbors a mix of different talents, backgrounds, competences, and interests. We offer a competitive compensation and benefits package. In line with the Austrian Science Fund’s salary scheme, a typical annual gross salary is slightly above EUR 35,000.